Anti-VEGF antibodies

Details Anti-VEGF antibodies Anti-VEGF antibodies

2006-01-27

2010-10-12

Huynh, Phuong (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S071100, C435S252330, C435S320100, C530S387100, C530S388230, C536S023530

Reexamination Certificate

active

07811785

ABSTRACT:
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

REFERENCES:
patent: 4774378 (1988-09-01), Faure et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5688666 (1997-11-01), Bass et al.
patent: 5723286 (1998-03-01), Dower et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5928641 (1999-07-01), Seon
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6172197 (2001-01-01), McCafferty et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 2007/0020267 (2007-01-01), Fuh et al.
patent: 2007/0141065 (2007-06-01), Fuh et al.
patent: 2 019 559 (1990-12-01), None
patent: 0 368 684 (2004-09-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 95/27062 (1995-10-01), None
patent: WO 97/45450 (1997-12-01), None
patent: WO00/34337 (2000-06-01), None
patent: WO 2005/012359 (2005-02-01), None
patent: WO 2005/044853 (2005-05-01), None
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Beiboer et al, J Mol Biol 296: 833-849, 2000.
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”Proc. Natl. Acad. Sci. USA79: 1979-1983 (1982).
Sone et al., “Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice,”Biochem. Biophys. Res. Commun. 281: 562-568 (2001).
Fuh et al., “Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab,”J. Biol. Chem. 281(10):6625-6631 (2006).
Liang et al., “Cross-Species Vascular Endothelial Growth Factor (VEGF)-Blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF,”J. Biol. Chem. 281(2): 951-961 (2006).
Lowman, “Optimization of Therapeutic Antibodies Using Monovalent Phage Display,”Presentation for Bio 2002 ConferenceJun. 12, 2002.
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”,Arch Ophthalmol., 114:66-71 (1996).
Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders”,The New England Journal of Medicine, 331:1480-1487 (1994).
Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity”,Proc. Natl. Acad. Sci. USA, 91:3809-3813 (1994).
Barbas et al., “Selection and evolution of high-affinity human anti-viral antibodies”,Tibtech, 14:230-234 (1996).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Proteins”,Proteins: Structure, Function and Genetics, 8:309-314 (1990).
Berkman et al., “Expression of the Vascular Permeability Factor/Vasculer Endothelial Growth Factor Gene in Central Nervous System Neoplasms”,J. Clin. Invest., 91:153-159 (1993).
Borgström et al., “Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-Vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy”,Cancer Research, 56:4032-4030 (1996).
Brekken et al., “Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium”,Cancer Research, 58:1952-1959 (1998).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract”,Cancer Research, 53:4727-4735 (1993).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer”,Hum Pathol., 26:86-91 (1995).
Carmeliet et al., “Angiogenesis in cancer and other diseases”,Nature, 407:249-257 (2000).
Carmeliet et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele”,Nature, 380:435-439 (1996).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”,Bio/Technology, 10:163-167 (1992).
Carter et al., “Humanization of an anti-p185Her2antibody for human cancer therapy”,Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”,J. Mol. Biol., 293:865-881 (1999).
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”,J. Mol. Biol., 196:901-917 (1987).
Christinger et al., “Crystallization of the Receptor Binding Domain of Vascular Endothelial Growth Factor”,Proteins: Structure, Function, and Genetics, 26:353-357 (1996).
Clackson et al., “Making antibody fragments using phage display libraries”,Nature, 352:624-628 (1991).
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”,Reports, 244:1081-1085 (1989).
de Wildt et al., “Antibody arrays for high-throughput screening of antibody-antigen interactions”,Nature Biotechnology, 18:989-994 (2000).
Deng et al., “Selection of Antibody Single-chain Variable Fragments with Improved Carbohydrate Binding by Phage Display”,The Journal of Biological Chemistry, 269(13):9533-9538 (1994).
Deshayes et al., “Rapid Identification of Small Binding Motifs with High-Throughput Phage Display: Discovery of Peptidic Antagonists of IGF-1 Function”,Chemistry&Biology, 9:495-505 (2002).
Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis”,American Journal of Pathology, 146(5):1029-1039 (1995).
Ferrara et al., “Vascular endothelial growth factor is essential for corpus luteum angiogenesis”,Nature Medicine, 4(3):336-340 (1998).
Ferrara et al., “Clinical applications of angiogenic growth factors and their inhibitors”,Nature Medicine, 5(12):1359-1364 (1999).
Ferrara et al., “Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins”,Endocrine Reviews, 13(1):18-32 (1992).
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor”,Endocrine Reviews, 18(1):4-25 (1997).
Ferrara, “Molecular and biological properties of vascular endothelial growth factor”,J. Mol. Med., 77:527-543 (1999).
Ferrara et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene”,Nature, 380:439-442 (1996).
Folkman et al., “Angiogenic Factors”,Science, 235(4787):442-447 (1987).
Garrard et al., “Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops”,Gene, 128:103-109 (1993).
Gerber et al., “VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formati

Affiliated with

Also associated with

Rating

Anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4160732